LAB
$0.98
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East,...
Recent News
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million
Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.
Standard BioTools: Q4 Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had net income of 5 cents. Earnings, adjusted for one-time gains and costs, came to 6 cents per share. The company that makes equipment to control fluids posted revenue of $23.8 million in the period.
Standard BioTools (NASDAQ:LAB) shareholders have endured a 76% loss from investing in the stock five years ago
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...
Institutional owners may consider drastic measures as Standard BioTools Inc.'s (NASDAQ:LAB) recent US$96m drop adds to long-term losses
Key Insights Significantly high institutional ownership implies Standard BioTools' stock price is sensitive to their...